Ping Lin

Efficacy and safety benefits of <scp>iGlarLixi</scp> versus insulin glargine 100 U/ <scp>mL</scp> or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The <scp>LixiLan‐O‐AP</scp> randomized controlled trial

Wenying Yang, Xiaolin Dong, Qingju Li et al. · Diabetes Obesity and Metabolism · 2022 · 31 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Improved glycaemic control and weight benefit with <scp>iGlarLixi</scp> versus insulin glargine 100 U/ <scp>mL</scp> in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the <scp>LixiLan‐L‐CN</scp> randomized controlled trial

Xiaoyong Yuan, Xiaohui Guo, Junqing Zhang et al. · Diabetes Obesity and Metabolism · 2022 · 27 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Predictive Value of Cardiovascular Health Score for Health Outcomes in Patients with PCI: Comparison between Life’s Simple 7 and Life’s Essential 8

Xueqin Gao, Xinrui Ma, Ping Lin et al. · International Journal of Environmental Research and Public Health · 2023 · 21 citations · Full text

Medicine, Cardiology, Interventional Cardiology +16

Type D personality as a risk factor for 3-year cardiovascular events in patients with coronary artery disease and their spouse: a prospective cohort study

Yini Wang, B Huang, Mengru Sun et al. · European Journal of Preventive Cardiology · 2024 · 13 citations · Full text

Education, Cardiology, Psychology +15